drug · small molecule

IGALMI

updated 5mo ago

by $BTAI BioXcel Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 investigational indications.

targets

Adrenergic receptor alpha-2

all catalysts(0)

nothing on the calendar yet

Trials studying IGALMI

phase4Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disordercompletedn=29
phase2The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Childrenrecruitingn=64
—A Study to Learn About the Study Medicine - Precedex in Children From Japan.completedn=111
—Precedex Special Investigation (in Pediatric Patients)completedn=111

News(1)

BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived assets as the biotech files for Chapter 11 bankruptcy.
biospace · 1mo ago

brand

IGALMI

trade names

Cepedex, Dexdomitor, Dexdor, Dexmedetomidine accord, Dexmedetomidine hydrochloride, Igalmi

generic

DEXMEDETOMIDINE HYDROCHLORIDE

MOA

12.1 Mechanism of Action Dexmedetomidine is an alpha-2 adrenergic receptor agonist. The mechanism of action of IGALMI in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder is thought to be due to activation of presynaptic alpha-2 adrenergic receptors.

indication

1 INDICATIONS AND USAGE IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI is an alpha-2 adrenergic receptor agonist indicated in adults for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder. ( 1 ) Limitations of Use : The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose. ( 1 , 5.4 , 5.5 ) Limitations of Use The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose [see Warnings and Precautions (5.4 , 5.5) ] .

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 3h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

IGALMI

updated 5mo ago

by $BTAI BioXcel Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 investigational indications.

targets

Adrenergic receptor alpha-2

all catalysts(0)

nothing on the calendar yet

Trials studying IGALMI

phase4Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disordercompletedn=29
phase2The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Childrenrecruitingn=64
—A Study to Learn About the Study Medicine - Precedex in Children From Japan.completedn=111
—Precedex Special Investigation (in Pediatric Patients)completedn=111

News(1)

BioXcel files for bankruptcy, will sell assets to Teva for up to $125M
Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived assets as the biotech files for Chapter 11 bankruptcy.
biospace · 1mo ago

brand

IGALMI

trade names

Cepedex, Dexdomitor, Dexdor, Dexmedetomidine accord, Dexmedetomidine hydrochloride, Igalmi

generic

DEXMEDETOMIDINE HYDROCHLORIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 3h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

IGALMI

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying IGALMI

News(1)

Report a data issue

comments(0)

IGALMI

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying IGALMI

News(1)

Report a data issue

comments(0)